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Background: Continuous flow (CF) left ventricular assist devices (LVADs) have been shown to improve quality of life (QoL) and functional capacity 
(FC) in patients (pts) with advanced heart failure (HF). We evaluated the impact of age, gender, and indication (bridge to transplant [BTT] vs 
destination therapy [DT]) on QoL and FC in pts with a CF LVAD.
Methods: We analyzed paired data from the multicenter HeartMate II LVAD BTT (n=90) and DT trials (n=200). HF-related QoL (Minnesota Living 
with Heart Failure [MLWHF], Kansas City Cardiomyopathy Questionnaires [KCCQ]) and FC (6-minute walk distance [6MWD]) at baseline and 6 
months were measured. Changes by gender and age in BTT and DT pts were compared.
Results: DT pts were older (62±12 vs 51±13), more had ischemic etiology (58% vs 46%), with similar percentage of women (25% vs 24%) vs BTT 
pts. There were significant improvements in QoL and FC in all pts at 6 months. No differences in the magnitude of improvement in QoL or FC were 
observed by gender or age. Improvements in QoL scores were greater in DT pts than in BTT pts for KCCQ (figure) and MLWHF scores (DT: Δ=39±28; 
BTT: Δ=28±28, p=0.003). Improvements in 6MWD after 6 months were similar (BTT: Δ=167±133m; DT Δ=205±184m, p=0.42).
Conclusions: All pts showed significant improvement in QoL with CF LVAD, but DT pts had more pronounced changes than BTT pts. This 
improvement cannot be directly attributed to age and may be related to severity of illness and comorbid conditions before LVAD support and greater 
QoL benefit during support. 
